vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and NVE CORP (NVEC). Click either name above to swap in a different company.
NVE CORP is the larger business by last-quarter revenue ($6.2M vs $4.8M, roughly 1.3× NovaBay Pharmaceuticals, Inc.). NVE CORP runs the higher net margin — 54.4% vs -25.5%, a 79.9% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs 22.9%). NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-4.8M). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs -6.3%).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
NVE Corporation develops and manufactures spintronic-based electronic components, including high-performance magnetoresistive sensors, couplers, and signal isolators. Its products are used in industrial automation, automotive systems, medical devices, and IoT applications, serving global original equipment manufacturers and electronic component distributors.
NBY vs NVEC — Head-to-Head
Income Statement — Q4 FY2024 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $6.2M |
| Net Profit | $-1.2M | $3.4M |
| Gross Margin | 65.2% | 78.6% |
| Operating Margin | -37.2% | 60.2% |
| Net Margin | -25.5% | 54.4% |
| Revenue YoY | 126.1% | 22.9% |
| Net Profit YoY | 70.5% | 11.0% |
| EPS (diluted) | — | $0.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.2M | ||
| Q3 25 | — | $6.3M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | $4.8M | $5.1M | ||
| Q3 24 | $0 | $6.8M | ||
| Q2 24 | $2.4M | $6.8M | ||
| Q1 24 | $2.6M | $7.1M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $3.3M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | $-1.2M | $3.0M | ||
| Q3 24 | $-1.2M | $4.0M | ||
| Q2 24 | $-1.6M | $4.1M | ||
| Q1 24 | $-3.2M | $3.8M |
| Q4 25 | — | 78.6% | ||
| Q3 25 | — | 78.3% | ||
| Q2 25 | — | 80.6% | ||
| Q1 25 | — | 79.2% | ||
| Q4 24 | 65.2% | 84.2% | ||
| Q3 24 | — | 86.0% | ||
| Q2 24 | 66.3% | 85.6% | ||
| Q1 24 | 68.2% | 75.5% |
| Q4 25 | — | 60.2% | ||
| Q3 25 | — | 57.6% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | -37.2% | 58.5% | ||
| Q3 24 | — | 65.0% | ||
| Q2 24 | -67.4% | 64.7% | ||
| Q1 24 | -87.1% | 57.3% |
| Q4 25 | — | 54.4% | ||
| Q3 25 | — | 52.2% | ||
| Q2 25 | — | 58.6% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | -25.5% | 60.2% | ||
| Q3 24 | — | 59.6% | ||
| Q2 24 | -66.0% | 60.4% | ||
| Q1 24 | -122.2% | 53.8% |
| Q4 25 | — | $0.70 | ||
| Q3 25 | — | $0.68 | ||
| Q2 25 | — | $0.74 | ||
| Q1 25 | — | $0.80 | ||
| Q4 24 | — | $0.63 | ||
| Q3 24 | $-1.92 | $0.83 | ||
| Q2 24 | $-1.37 | $0.85 | ||
| Q1 24 | $-29.95 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $20.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $58.3M |
| Total Assets | $3.4M | $60.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.6M | ||
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $15.8M | ||
| Q1 25 | — | $21.7M | ||
| Q4 24 | $430.0K | $20.4M | ||
| Q3 24 | $776.0K | $22.9M | ||
| Q2 24 | $751.0K | $21.7M | ||
| Q1 24 | $1.8M | $22.2M |
| Q4 25 | — | $58.3M | ||
| Q3 25 | — | $59.7M | ||
| Q2 25 | — | $61.1M | ||
| Q1 25 | — | $62.3M | ||
| Q4 24 | $-129.0K | $63.0M | ||
| Q3 24 | $1.1M | $64.9M | ||
| Q2 24 | $-617.0K | $64.9M | ||
| Q1 24 | $160.0K | $65.6M |
| Q4 25 | — | $60.0M | ||
| Q3 25 | — | $61.5M | ||
| Q2 25 | — | $63.6M | ||
| Q1 25 | — | $64.3M | ||
| Q4 24 | $3.4M | $64.6M | ||
| Q3 24 | $3.9M | $65.9M | ||
| Q2 24 | $3.9M | $66.7M | ||
| Q1 24 | $5.4M | $66.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $4.2M |
| Free Cash FlowOCF − Capex | $-1.7M | $-4.8M |
| FCF MarginFCF / Revenue | -35.4% | -77.0% |
| Capex IntensityCapex / Revenue | 0.1% | 144.3% |
| Cash ConversionOCF / Net Profit | — | 1.24× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $2.8M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | — | $2.5M | ||
| Q4 24 | $-1.7M | $3.8M | ||
| Q3 24 | $-2.4M | $2.1M | ||
| Q2 24 | $-1.4M | $5.9M | ||
| Q1 24 | $-2.0M | $3.1M |
| Q4 25 | — | $-4.8M | ||
| Q3 25 | — | $2.7M | ||
| Q2 25 | — | $4.1M | ||
| Q1 25 | — | $-7.5M | ||
| Q4 24 | $-1.7M | $-6.3M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | -77.0% | ||
| Q3 25 | — | 42.9% | ||
| Q2 25 | — | 67.7% | ||
| Q1 25 | — | -103.7% | ||
| Q4 24 | -35.4% | -124.7% | ||
| Q3 24 | — | 28.5% | ||
| Q2 24 | — | 72.8% | ||
| Q1 24 | -75.3% | — |
| Q4 25 | — | 144.3% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | 17.3% | ||
| Q1 25 | — | 137.9% | ||
| Q4 24 | 0.1% | 200.6% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | 0.0% | 13.5% | ||
| Q1 24 | 0.1% | 0.0% |
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 0.84× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 0.64× | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 1.43× | ||
| Q1 24 | — | 0.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
NVEC
Segment breakdown not available.
